Sunitinib |
n = 11 |
n =10 |
|
Age (mean ± SD), years |
66.5 ± 8.3 |
67.8 ± 5.8 |
0.673 |
Gender; Male/Female, n (%) |
6/5 (45.5) |
8/2 (20.0) |
0.217 |
Performance Status; 0/1 |
7/4 (36.4) |
6/4 (40.0) |
0.864 |
Pathological Type; Conventional |
11 (100.0) |
8 (80.0) |
0.297 |
Fuhrman grade; 2/3+4 |
1/10 (90.9) |
2/8 (80.0) |
0.476 |
pT stage; 1+2/3+4 |
2/9 (81.8) |
3/7 (70.0) |
0.525 |
Lymph Node Metastasis; Presence |
7 (63.6) |
6 (60.0) |
0.864 |
Distant Metastasis; Presence |
9 (81.8) |
8 (80.0) |
0.916 |
Neo-Adjuvant Setting; Yes |
1 (9.1) |
0 (0.0) |
0.329 |
Past Therapy Used TKI; Presence |
1 (9.1) |
0 (0.0) |
0.329 |
Others |
n = 6 |
n = 6 |
|
Age (mean ± SD); years |
64.5 ± 3.8 |
72.5 ± 5.3 |
0.013 |
Gender; Male / Female |
6/0 (0.0) |
3/3 (50.0) |
0.182 |
Performance Status; 0/1 |
2/4 (66.7) |
1/5 (83.3) |
0.505 |
Pathological Type; Conventional |
5 (83.3) |
5 (83.3) |
0.999 |
Fuhrman grade; 2/3+4 |
1/5 (83.3) |
3/3 (50.0) |
0.221 |
pT Stage; 1+2/3+4 |
1/5 (83.3) |
2/4 (66.7) |
0.501 |
LN Metastasis; Presence |
3 (50.0) |
3 (50.0) |
0.999 |
Distant Metastasis; Presence |
6 (100.0) |
4 (66.7) |
0.121 |
Neo-Adjuvant Setting; Yes |
0 (0.0) |
1 (16.7) |
0.296 |
Past Therapy Used TKI; Presence |
1 (16.7) |
2 (33.3) |
0.505 |